Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Zheng-Yi Zhou, Shawn Sun, Pooja Chopra, Yichen Zhong, Todor Totev & James Signorovitch. (2015) Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics 18:11, pages 919-929.
Read now
Read now
Junling Wang, Xianchen Liu & C. Daniel Mullins. (2011) Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. Current Medical Research and Opinion 27:7, pages 1303-1313.
Read now
Read now
Antoni Sicras-Mainar, Ruth Navarro-Artieda, Milagrosa Blanca-Tamayo, Victoria Gimeno-de la Fuente & Jordi Salvatella-Pasant. (2010) Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences. Current Medical Research and Opinion 26:12, pages 2757-2764.
Read now
Read now
Larry Ereshefsky, Delphine Saragoussi, Nicolas Despiégel, Karina Hansen, Clément François & Khaled Maman. (2010) The 6-month persistence on SSRIs and associated economic burden. Journal of Medical Economics 13:3, pages 527-536.
Read now
Read now
Eric Q. Wu, Rym Ben-Hamadi, Andrew P. Yu, Jackson Tang, M. Haim Erder & Anjana Bose. (2010) Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. Journal of Medical Economics 13:2, pages 314-323.
Read now
Read now
Eric Wu, Paul Greenberg, Elaine Yang, Andrew Yu, Rym Ben-Hamadi & M. Haim Erder. (2008) Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Current Medical Research and Opinion 24:10, pages 2805-2813.
Read now
Read now
Articles from other publishers (15)
Kazi Ishtiak-AhmedKatherine L. MuslinerKaj Sparle ChristensenErik Lykke MortensenAndrew A. NierenbergChristiane Gasse. (2023) Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark. American Journal of Psychiatry.
Crossref
Crossref
Lisa A. Kilpatrick, Beatrix Krause‐Sorio, Prabha Siddarth, Katherine L. Narr & Helen Lavretsky. (2022) Default mode network connectivity and treatment response in geriatric depression. Brain and Behavior 12:4.
Crossref
Crossref
Iona K. Machado, Csilla Lippert & Michael J. Ostacher. (2021) Incorporating clinical research into recommendations for addressing global mental health needs: Updating the World Health Organization's Essential Medicines List. Comprehensive Psychiatry 109, pages 152245.
Crossref
Crossref
Helen Lavretsky, Kelsey T. Laird, Beatrix Krause-Sorio, Brandon F. Heimberg, Jillian Yeargin, Adrienne Grzenda, Pauline Wu, Kitikan Thana-Udom, Linda M. Ercoli & Prabha Siddarth. (2020) A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints. The American Journal of Geriatric Psychiatry 28:2, pages 178-190.
Crossref
Crossref
Yulong Cai, Lian Wang, Ivan Nalvarte, Rui Xiao, Xin Li & Xiaotang Fan. (2019) Citalopram attenuates social behavior deficits in the BTBR T+Itpr3tf/J mouse model of autism. Brain Research Bulletin 150, pages 75-85.
Crossref
Crossref
Mehnaz Ahmed, Marlene Malik, Johannes Teselink, Krista L. Lanctôt & Nathan Herrmann. (2019) Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia. Drugs & Aging 36:7, pages 589-605.
Crossref
Crossref
Joseph Bergman, Paul P. Lerner, Shmuel Sokolik, Vladimir Lerner, Anatoly Kreinin & Chanoch Miodownik. (2017) Successful Use of Escitalopram for the Treatment of Visual Hallucinations in Patients With Parkinson Disease. Clinical Neuropharmacology 40:6, pages 246-250.
Crossref
Crossref
Andrea Cipriani, Marianna Purgato, Toshi A Furukawa, Carlotta Trespidi, Giuseppe Imperadore, Alessandra Signoretti, Rachel Churchill, Norio Watanabe & Corrado Barbui. (2012) Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Yi-Ju Pan, Martin Knapp & Paul McCrone. (2012) Cost-effectiveness comparisons between antidepressant treatments in depression: Evidence from database analyses and prospective studies. Journal of Affective Disorders 139:2, pages 113-125.
Crossref
Crossref
Yoram Barak, Igor Plopski, Shelly Tadger & Diana Paleacu. (2011) Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. International Psychogeriatrics 23:9, pages 1515-1519.
Crossref
Crossref
Jian-Jun Ou, Guang-Lei Xun, Ren-Rong Wu, Le-Hua Li, Mao-Sheng Fang, Hong-Geng Zhang, Shi-Ping Xie, Jian-Guo Shi, Bo Du, Xue-Qin Yuan & Jing-Ping Zhao. (2010) Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology 213:2-3, pages 639-646.
Crossref
Crossref
Dallas P. Seitz, Sudeep S. Gill & David K. Conn. (2010) Citalopram versus other antidepressants for late‐life depression: a systematic review and meta‐analysis. International Journal of Geriatric Psychiatry 25:12, pages 1296-1305.
Crossref
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref
Crossref
Hans Förstl, Marion M. Lautenschlager, Nicola T. Lautenschlager & Gerd Laux. 2010. Grundlagen der Neuro-Psychopharmakologie. Grundlagen der Neuro-Psychopharmakologie
521
536
.
. (2009) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 24:4.
Crossref
Crossref